Skip to Main Content

Paper Details

Alirocumab for hyperlipidemia: physiology of PCSK9 inhibition, pharmacodynamics and Phase I and II clinical trial results of a PCSK9 monoclonal antibody.
Future Cardiol
38
2014

Datasets

Release 1.2